nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—FGF2—Signaling by PDGF—HRAS—ocular cancer	0.000514	0.000514	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAML2—ocular cancer	0.000509	0.000509	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HDAC1—ocular cancer	0.000507	0.000507	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—AKT1—ocular cancer	0.000501	0.000501	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—AKT1—ocular cancer	0.000498	0.000498	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—AKT1—ocular cancer	0.000496	0.000496	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—AKT1—ocular cancer	0.000494	0.000494	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—HRAS—ocular cancer	0.000487	0.000487	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—AKT1—ocular cancer	0.000486	0.000486	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—ocular cancer	0.000486	0.000486	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TFDP1—ocular cancer	0.000485	0.000485	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—TGFB1—ocular cancer	0.000485	0.000485	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MDM2—ocular cancer	0.000484	0.000484	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.000477	0.000477	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CDKN2B—ocular cancer	0.000476	0.000476	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CDKN1B—ocular cancer	0.000472	0.000472	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—HRAS—ocular cancer	0.000468	0.000468	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—HRAS—ocular cancer	0.000466	0.000466	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—E2F5—ocular cancer	0.000465	0.000465	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—AKT1—ocular cancer	0.000464	0.000464	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—AKT1—ocular cancer	0.000464	0.000464	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—AKT1—ocular cancer	0.000464	0.000464	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—ocular cancer	0.000463	0.000463	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—HRAS—ocular cancer	0.00046	0.00046	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—AKT1—ocular cancer	0.00046	0.00046	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—AKT1—ocular cancer	0.000456	0.000456	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—E2F4—ocular cancer	0.000456	0.000456	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CDKN2B—ocular cancer	0.000455	0.000455	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—AKT1—ocular cancer	0.000454	0.000454	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—ocular cancer	0.000448	0.000448	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RBL1—ocular cancer	0.000447	0.000447	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNA11—ocular cancer	0.000444	0.000444	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—CDKN1B—ocular cancer	0.000442	0.000442	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—HRAS—ocular cancer	0.000441	0.000441	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.000437	0.000437	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CDKN1A—ocular cancer	0.000435	0.000435	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—AKT1—ocular cancer	0.00043	0.00043	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—HRAS—ocular cancer	0.000423	0.000423	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—HRAS—ocular cancer	0.000421	0.000421	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—ocular cancer	0.000419	0.000419	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—ocular cancer	0.000419	0.000419	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—E2F1—ocular cancer	0.000417	0.000417	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—ocular cancer	0.000417	0.000417	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—HRAS—ocular cancer	0.000415	0.000415	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—EP300—ocular cancer	0.000414	0.000414	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—AKT1—ocular cancer	0.000413	0.000413	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNAQ—ocular cancer	0.000413	0.000413	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—AKT1—ocular cancer	0.000411	0.000411	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.000411	0.000411	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—ocular cancer	0.000409	0.000409	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAML2—ocular cancer	0.000409	0.000409	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSPH—ocular cancer	0.000409	0.000409	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—CDKN1A—ocular cancer	0.000408	0.000408	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TGFB1—ocular cancer	0.000407	0.000407	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—AKT1—ocular cancer	0.000406	0.000406	CbGpPWpGaD
Sirolimus—FGF2—Disease—HDAC1—ocular cancer	0.000403	0.000403	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—ocular cancer	0.000395	0.000395	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—ocular cancer	0.000391	0.000391	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—ocular cancer	0.00039	0.00039	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—ocular cancer	0.00039	0.00039	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—ocular cancer	0.00039	0.00039	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MDM2—ocular cancer	0.00039	0.00039	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—AKT1—ocular cancer	0.000389	0.000389	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	0.000389	0.000389	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—E2F3—ocular cancer	0.000387	0.000387	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—ocular cancer	0.000387	0.000387	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAML2—ocular cancer	0.000386	0.000386	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—ocular cancer	0.000383	0.000383	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—ocular cancer	0.000382	0.000382	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—AKT1—ocular cancer	0.000374	0.000374	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MDM2—ocular cancer	0.000372	0.000372	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HDAC1—ocular cancer	0.000372	0.000372	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—AKT1—ocular cancer	0.000372	0.000372	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—AKT1—ocular cancer	0.00037	0.00037	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—ocular cancer	0.00037	0.00037	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—AKT1—ocular cancer	0.000368	0.000368	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—AKT1—ocular cancer	0.000366	0.000366	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—ocular cancer	0.000361	0.000361	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—ocular cancer	0.000361	0.000361	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN2B—ocular cancer	0.000361	0.000361	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TFDP1—ocular cancer	0.00036	0.00036	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—ocular cancer	0.000358	0.000358	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—MDM2—ocular cancer	0.000358	0.000358	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CDKN1B—ocular cancer	0.000356	0.000356	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—ocular cancer	0.000346	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—ocular cancer	0.000345	0.000345	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—AKT1—ocular cancer	0.000345	0.000345	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—AKT1—ocular cancer	0.000345	0.000345	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—AKT1—ocular cancer	0.000341	0.000341	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CDKN1B—ocular cancer	0.00034	0.00034	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—ocular cancer	0.000338	0.000338	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EP300—ocular cancer	0.000338	0.000338	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—AKT1—ocular cancer	0.000337	0.000337	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNA11—ocular cancer	0.000336	0.000336	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN2B—ocular cancer	0.000334	0.000334	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CDKN1A—ocular cancer	0.000329	0.000329	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—ocular cancer	0.000327	0.000327	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CDKN1B—ocular cancer	0.000326	0.000326	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—AKT1—ocular cancer	0.000319	0.000319	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—AKT1—ocular cancer	0.000316	0.000316	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CDKN1A—ocular cancer	0.000314	0.000314	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNAQ—ocular cancer	0.000313	0.000313	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EP300—ocular cancer	0.000313	0.000313	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—E2F1—ocular cancer	0.000306	0.000306	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—ocular cancer	0.000305	0.000305	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CDKN1A—ocular cancer	0.000301	0.000301	CbGpPWpGaD
Sirolimus—MTOR—Disease—HDAC1—ocular cancer	0.000299	0.000299	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EP300—ocular cancer	0.000299	0.000299	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—ocular cancer	0.000296	0.000296	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—ocular cancer	0.000294	0.000294	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	0.000288	0.000288	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAML2—ocular cancer	0.000286	0.000286	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HDAC1—ocular cancer	0.000282	0.000282	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MDM2—ocular cancer	0.000276	0.000276	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—ocular cancer	0.000271	0.000271	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN2B—ocular cancer	0.000268	0.000268	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—ocular cancer	0.000266	0.000266	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—MDM2—ocular cancer	0.000265	0.000265	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MDM2—ocular cancer	0.000264	0.000264	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	0.000263	0.000263	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNA11—ocular cancer	0.000257	0.000257	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN2B—ocular cancer	0.000253	0.000253	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CDKN1B—ocular cancer	0.000252	0.000252	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MDM2—ocular cancer	0.000252	0.000252	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSPH—ocular cancer	0.000252	0.000252	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	0.000251	0.000251	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNA11—ocular cancer	0.00025	0.00025	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	0.000243	0.000243	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDKN1B—ocular cancer	0.000242	0.000242	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CDKN1B—ocular cancer	0.000241	0.000241	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNAQ—ocular cancer	0.000239	0.000239	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNA11—ocular cancer	0.000236	0.000236	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—AKT1—ocular cancer	0.000235	0.000235	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CDKN1A—ocular cancer	0.000233	0.000233	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNAQ—ocular cancer	0.000232	0.000232	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—E2F1—ocular cancer	0.000232	0.000232	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—ocular cancer	0.000231	0.000231	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	0.000231	0.000231	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CDKN1B—ocular cancer	0.00023	0.00023	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDKN1A—ocular cancer	0.000224	0.000224	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CDKN1A—ocular cancer	0.000223	0.000223	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EP300—ocular cancer	0.000222	0.000222	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—ocular cancer	0.00022	0.00022	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNAQ—ocular cancer	0.000219	0.000219	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MDM2—ocular cancer	0.000217	0.000217	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—ocular cancer	0.000214	0.000214	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CDKN1A—ocular cancer	0.000213	0.000213	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EP300—ocular cancer	0.000212	0.000212	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HDAC1—ocular cancer	0.000209	0.000209	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—ocular cancer	0.000204	0.000204	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—AKT1—ocular cancer	0.000204	0.000204	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EP300—ocular cancer	0.000202	0.000202	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	0.000201	0.000201	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	0.000201	0.000201	CbGpPWpGaD
Sirolimus—FGF2—Disease—MDM2—ocular cancer	0.0002	0.0002	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDKN1B—ocular cancer	0.000198	0.000198	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—ocular cancer	0.000196	0.000196	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	0.000193	0.000193	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—ocular cancer	0.000189	0.000189	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—ocular cancer	0.000188	0.000188	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN2B—ocular cancer	0.000188	0.000188	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MDM2—ocular cancer	0.000185	0.000185	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—ocular cancer	0.000185	0.000185	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—ocular cancer	0.000184	0.000184	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1B—ocular cancer	0.000183	0.000183	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDKN1A—ocular cancer	0.000183	0.000183	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—ocular cancer	0.00018	0.00018	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—ocular cancer	0.000176	0.000176	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—ocular cancer	0.000176	0.000176	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EP300—ocular cancer	0.000174	0.000174	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—ocular cancer	0.000173	0.000173	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—E2F1—ocular cancer	0.000172	0.000172	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNA11—ocular cancer	0.00017	0.00017	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1B—ocular cancer	0.000169	0.000169	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1A—ocular cancer	0.000169	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	0.000165	0.000165	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—ocular cancer	0.000161	0.000161	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MDM2—ocular cancer	0.000161	0.000161	CbGpPWpGaD
Sirolimus—FGF2—Disease—EP300—ocular cancer	0.000161	0.000161	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNAQ—ocular cancer	0.000158	0.000158	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1A—ocular cancer	0.000156	0.000156	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—ocular cancer	0.000152	0.000152	CbGpPWpGaD
Sirolimus—MTOR—Disease—MDM2—ocular cancer	0.000149	0.000149	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EP300—ocular cancer	0.000148	0.000148	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1B—ocular cancer	0.000147	0.000147	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—ocular cancer	0.000146	0.000146	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—ocular cancer	0.000145	0.000145	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—ocular cancer	0.000145	0.000145	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MDM2—ocular cancer	0.00014	0.00014	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—ocular cancer	0.00014	0.00014	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.00014	0.00014	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—ocular cancer	0.00014	0.00014	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—ocular cancer	0.000138	0.000138	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1B—ocular cancer	0.000136	0.000136	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—ocular cancer	0.000136	0.000136	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—ocular cancer	0.000134	0.000134	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—ocular cancer	0.000129	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EP300—ocular cancer	0.000129	0.000129	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—ocular cancer	0.000129	0.000129	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNA11—ocular cancer	0.000129	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—ocular cancer	0.000129	0.000129	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1B—ocular cancer	0.000128	0.000128	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—ocular cancer	0.000128	0.000128	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—ocular cancer	0.000125	0.000125	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—ocular cancer	0.000122	0.000122	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—ocular cancer	0.000122	0.000122	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNAQ—ocular cancer	0.00012	0.00012	CbGpPWpGaD
Sirolimus—MTOR—Disease—EP300—ocular cancer	0.000119	0.000119	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—ocular cancer	0.000119	0.000119	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—ocular cancer	0.000118	0.000118	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EP300—ocular cancer	0.000112	0.000112	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—ocular cancer	0.00011	0.00011	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—ocular cancer	0.000106	0.000106	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—ocular cancer	0.000105	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MDM2—ocular cancer	0.000104	0.000104	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—ocular cancer	0.000104	0.000104	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—ocular cancer	0.000104	0.000104	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—ocular cancer	0.000102	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—ocular cancer	9.8e-05	9.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—ocular cancer	9.77e-05	9.77e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—ocular cancer	9.7e-05	9.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1B—ocular cancer	9.5e-05	9.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—ocular cancer	9.06e-05	9.06e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—ocular cancer	8.96e-05	8.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—ocular cancer	8.83e-05	8.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—ocular cancer	8.77e-05	8.77e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—EP300—ocular cancer	8.58e-05	8.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EP300—ocular cancer	8.34e-05	8.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—ocular cancer	8.15e-05	8.15e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—ocular cancer	8.04e-05	8.04e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNA11—ocular cancer	7.92e-05	7.92e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—EP300—ocular cancer	7.87e-05	7.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—ocular cancer	7.8e-05	7.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—ocular cancer	7.69e-05	7.69e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNAQ—ocular cancer	7.36e-05	7.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—ocular cancer	7.27e-05	7.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—ocular cancer	7.25e-05	7.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—ocular cancer	7.2e-05	7.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—ocular cancer	6.79e-05	6.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—ocular cancer	5.97e-05	5.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—ocular cancer	5.71e-05	5.71e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—EP300—ocular cancer	5.69e-05	5.69e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—ocular cancer	5.18e-05	5.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—ocular cancer	5.04e-05	5.04e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—ocular cancer	4.76e-05	4.76e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—EP300—ocular cancer	4.3e-05	4.3e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—ocular cancer	3.44e-05	3.44e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—EP300—ocular cancer	2.65e-05	2.65e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—ocular cancer	2.6e-05	2.6e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—ocular cancer	1.6e-05	1.6e-05	CbGpPWpGaD
